Nariman Sadri, CEO of Darman Ara Company and Plasma Industry Activist, at the End of Year Pharmaceutical Conference 1403:
Four Prerequisites for Biotech Development:
Formulating a realistic national program and ensuring the commitment of governments to implement it, independent of changes in government officials.
Investment in infrastructure through a public private mix and supporting investments by liberalizing prices and commercializing innovations.
Strengthening regulators and enforcing quality standards to ensure consumer confidence.
Preparing the business environment and fostering international collaborations to develop markets.
The experience and path of the plasma industry in Iran show that we are far from having a cohesive national program.
2004: A decision was made to privatize the plasma industry.
2009: Investment in this sector should be done by the government.
2013: A decision to collect private investments.
2016: A decision to privatize the state owned plasma refinery.
2017: Stopping the development of the plasma industry in the private sector and transferring it to the Blood Transfusion Organization.
2020: During the COVID-19 crisis, there was an increase in imports of plasma products.
2021: Return to the policy of private sector investment.
2025: Three plasma collection centers were shut down by order of provincial authorities because the new policy emphasizes state control of this industry.
The center in Gorgan, which was approved by the Food and Drug Organization, was supposed to open on Tuesday, but we heard that if it opens on Tuesday, it will be closed by the Blood Transfusion Organization on Wednesday!
